Xencor up 12% on positive XmAb 14045 data [Seeking Alpha]
Xencor, Inc. (XNCR)
Last xencor, inc. earnings: 2/24 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.xencor.com/investor-relations
Company Research
Source: Seeking Alpha
Thinly trade Xencor ( XNCR ) is up on below-average volume following its announcement initial data from a Phase 1 dose-escalation study evaluating XmAb 14045 in patients with relapsed/refractory acute myeloid leukemia (AML). The results will be presented at ASH next month. At data cutoff, 64 patients had received XmAb 14045, a bispecific antibody targeting CD123 and CD3 (63 with AML and one with B cell ALL). All were heavily pretreated with a median of three prior lines of therapies. 30% (n=19/64) had undergone allogeneic stem cell transplantation. 23% (n=3/13) of evaluable AML patients achieved complete remission or complete remission with incomplete hematologic recovery at the two highest dose levels. 77% (n=49/64) developed cytokine release syndrome (CRS), with 11% (n=7/64) deemed serious or life-threatening. CRS was generally manageable with premedication. The company will host an analyst and investor event on Monday, December 3 at 8:00 pm pacific time to discus
Show less
Read more
Impact Snapshot
Event Time:
XNCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XNCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XNCR alerts
High impacting Xencor, Inc. news events
Weekly update
A roundup of the hottest topics
XNCR
News
- Vulvar Cancer Pipeline Insight 2024, with Key Focus on TAK-242, Vudalimab, PEN-866, Artesunate, IRX-2, ISA101, VicOryx, PRV111, PRGN-2009, ABI-2280 and CUE-101 [Yahoo! Finance]Yahoo! Finance
- Xencor, Inc. (NASDAQ: XNCR) had its price target lowered by analysts at BTIG Research from $56.00 to $38.00. They now have a "buy" rating on the stock.MarketBeat
- VIR-2218 + VIR- 3434 for Chronic Hepatitis B Drug Landscape Report 2024: 7MM Market Size, Forecast, and Emerging Insights 2019-2032 [Yahoo! Finance]Yahoo! Finance
- Xencor Appoints Bart Cornelissen as Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
- Xencor Appoints Bart Cornelissen as Chief Financial OfficerBusiness Wire
XNCR
Earnings
- 2/27/24 - Miss
XNCR
Sec Filings
- 4/24/24 - Form ARS
- 4/24/24 - Form DEFA14A
- 4/24/24 - Form DEF
- XNCR's page on the SEC website